Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
This article was originally published in The Tan Sheet
Executive Summary
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
You may also be interested in...
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
Xenical Switch Proposal Will Face Advisory Committee Review In January
GlaxoSmithKline's Rx-to-OTC switch application for a 60 mg dose of orlistat (Xenical) will be reviewed during a joint meeting of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees Jan. 23, according to the agency
Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
The "behavior modification" effect ofXenical adverse events could help allay concerns that OTC availability would lead to people using orlistat without making appropriate adjustments to their diets, according to the principal investigator of a study on the drug